Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 7.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 157,409 shares of the biotechnology company’s stock after purchasing an additional 11,439 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Exelixis were worth $3,008,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. boosted its stake in Exelixis by 4.9% during the 1st quarter. BlackRock Inc. now owns 36,214,174 shares of the biotechnology company’s stock valued at $702,917,000 after purchasing an additional 1,683,880 shares during the last quarter. Vanguard Group Inc. boosted its stake in Exelixis by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 31,284,832 shares of the biotechnology company’s stock valued at $490,546,000 after purchasing an additional 220,099 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Exelixis by 115.9% during the 1st quarter. Farallon Capital Management LLC now owns 23,466,000 shares of the biotechnology company’s stock valued at $455,475,000 after buying an additional 12,597,851 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Exelixis by 2.1% during the 1st quarter. Renaissance Technologies LLC now owns 15,279,389 shares of the biotechnology company’s stock valued at $296,573,000 after buying an additional 318,300 shares during the period. Finally, State Street Corp lifted its holdings in shares of Exelixis by 3.4% during the 3rd quarter. State Street Corp now owns 13,019,900 shares of the biotechnology company’s stock valued at $204,152,000 after buying an additional 423,520 shares during the period. 93.09% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the company. Bank of America increased their price target on Exelixis from $25.00 to $27.00 in a report on Thursday, October 12th. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a report on Friday, November 3rd. HC Wainwright initiated coverage on Exelixis in a report on Tuesday, September 26th. They set a “buy” rating and a $28.00 price target on the stock. Truist Financial reaffirmed a “buy” rating and issued a $32.00 target price on shares of Exelixis in a report on Wednesday, September 13th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $27.00 target price on shares of Exelixis in a report on Monday, November 13th. Five research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $25.44.
In related news, EVP Dana Aftab sold 4,600 shares of Exelixis stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $22.47, for a total value of $103,362.00. Following the completion of the transaction, the executive vice president now owns 399,943 shares in the company, valued at $8,986,719.21. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.90% of the company’s stock.
Exelixis Stock Up 0.7 %
Shares of Exelixis stock opened at $21.13 on Monday. The firm has a market cap of $6.57 billion, a price-to-earnings ratio of 75.46, a PEG ratio of 1.16 and a beta of 0.59. The business has a 50-day moving average price of $21.30 and a 200-day moving average price of $20.47. Exelixis, Inc. has a twelve month low of $15.32 and a twelve month high of $22.80.
Exelixis (NASDAQ:EXEL – Get Free Report) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.07). The firm had revenue of $471.90 million for the quarter, compared to analysts’ expectations of $473.31 million. Exelixis had a net margin of 5.19% and a return on equity of 3.71%. The company’s revenue for the quarter was up 14.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.23 EPS. On average, equities analysts expect that Exelixis, Inc. will post 0.62 EPS for the current fiscal year.
Exelixis Company Profile
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
- Five stocks we like better than Exelixis
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- How to Invest in Insurance Companies: A Guide
- MarketBeat Week in Review – 11/13 – 11/17
- Basic Materials Stocks Investing
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.